Injection treatment for severe lupus
Part of Immune system & allergy clinical trials.
This study tests a new injection called ACG102 for people with lupus that has not improved with standard treatments. The goal is to see if it can help control active lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a lupus diagnosis.
- Your lupus symptoms must be active and not well controlled by current treatments.
- You must be on a stable dose of your current lupus medications for at least 4 weeks before joining.
- You must be healthy enough in terms of organ function, and not have severe infections, liver or heart disease, recent cancer, or certain immune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SYS6020 given as an injection. It is for people with active lupus that hasn't improved with standard treatments. The goal is to see if it's safe and effective.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This study tests an experimental injection called ZM001 for people with severe lupus that hasn't improved with standard treatments. The goal is to see if this new therapy can help control the disease.
This study tests an investigational drug called ACE1831 for people with active systemic lupus erythematosus (lupus) whose disease has not improved with usual treatments. The goal is to see if ACE1831 can reduce lupus activity and help control symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
Hear when a new Refractory Active Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.